Press coverage about Adamas Pharmaceuticals (NASDAQ:ADMS) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 46.6645671559696 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Several equities research analysts have recently weighed in on the stock. BidaskClub lowered shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. Noble Financial reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Friday, May 12th. Mizuho reiterated a “buy” rating and issued a $26.00 target price on shares of Adamas Pharmaceuticals in a report on Tuesday, June 6th. Finally, Cowen and Company reiterated an “outperform” rating and issued a $45.00 target price on shares of Adamas Pharmaceuticals in a report on Sunday, May 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $29.00.

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) opened at 17.21 on Monday. The stock’s market cap is $384.80 million. Adamas Pharmaceuticals has a 12-month low of $12.10 and a 12-month high of $19.50. The company’s 50-day moving average is $17.39 and its 200-day moving average is $16.84.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.72). Adamas Pharmaceuticals had a negative return on equity of 45.19% and a negative net margin of 10,499.65%. During the same period in the previous year, the company posted ($0.65) earnings per share. On average, equities research analysts anticipate that Adamas Pharmaceuticals will post ($3.47) earnings per share for the current year.

In other Adamas Pharmaceuticals news, major shareholder Great Point Partners Llc sold 380,000 shares of the company’s stock in a transaction on Wednesday, June 21st. The stock was sold at an average price of $17.08, for a total value of $6,490,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders sold 731,041 shares of company stock valued at $12,476,149. 29.00% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Insider Buying and Selling by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.